CooperVision organic growth is the entire thesis — and it just printed 3%.

CooperVision is ~67% of revenue and essentially all the multiple — a daily-lens oligopoly with mid-30s EBITDA margin and pricing power through eye-care professionals. At 8% organic it was a 25-30x stock; at 3-5% it is a 14-18x stock. Management blames tough comps, China tariffs, and a reorg-muddled P&L. The FY25 guide was cut twice before landing 300bp below the initial midpoint. Q2 FY26 (late May) is the first chance to print above 5% in four quarters — that single number decides whether the re-rating is a trough or a line.

Two activists landed in one quarter and the board folded.

• Oct-Nov 2025. Jana Partners disclosed a top position pushing a CooperVision merger with Bausch+Lomb; Browning West ($500M+ invested) nominated four directors and demanded a CooperSurgical strategic review, citing a cumulative ROIC below 5% on ~$4B deployed into the segment.
• Dec 4, 2025. Cooper capitulated — announced a formal strategic review, added Walter Rosebrough (ex-STERIS CEO, 18% CAGR over 14 years) to the board, agreed to seriously consider him for Chair by year-end 2026, and expanded buyback authorization to $2B. Stock jumped ~12% after hours.
• The governance tell. Until FY2026, executive incentives had no ROIC or TSR gate; the FY23-FY25 PSU cycle paid out at the 200% maximum while the stock underperformed the S&P 500 healthcare index by over 100 points. The board added a 25% relative-TSR weight for FY2026 grants only after Browning West's letter.

Cheapest multiple since 2013 on a business that just printed a four-year margin high.

Operating margin collapsed from 19.5% in Q4 FY24 to 13.2% in Q4 FY25 on inventory build, FX, and tariffs — then snapped back to 20.8% in Q1 FY26 with eight straight EPS beats. Capex peaked in FY23-24 as new Costa Rica and Puerto Rico lens capacity came online and is normalizing toward 6-7% of sales. The multiple sits 1.3 standard deviations below the five-year mean; the Quality Score (90/100), ROIC (23%), and Altman Z (3.44) all argue this is not a value trap. Management has committed to $2.2B of cumulative FCF across FY26-FY28 — a 70% step-up from the FY25 run-rate that requires the CVI re-acceleration to land.

The tape is confirming the bear, not contradicting it.

• Down-trend regime. Price at $64.96 sits 12.8% below a flattening 200-day ($74.50), the 50-day just rolled under the 200-day, and every rally since the August 2024 peak near $112 has failed at a lower high. Relative to the S&P 500, COO has given back ~100 points over three years; relative to XLV, ~40 points — and both gaps are still widening.
• Oversold bounce, not a reversal. RSI printed 26 on April 23 — the third oversold reading in twelve months. The prior two were followed by 1-3 week bounces, not durable lows. Realized vol at 25% is squarely normal: no capitulation, no complacency, just persistent selling.
• Two levels that matter. A decisive weekly close above $82 — the December/February swing high and declining 100-day — forces a view change. A weekly close below the 52-week low of $61.80 on elevated volume opens a measured move toward the 2022 cycle low near $58.